Drugs facing NCE-1 in 2025

1. Amondys 45 patent expiration

AMONDYS 45's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9416361 SAREPTA THERAPS INC Splice-region antisense composition and method
May, 2021

(3 years ago)

US9447415 SAREPTA THERAPS INC Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Jun, 2025

(11 months from now)

USRE48960 SAREPTA THERAPS INC Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Jun, 2025

(11 months from now)

US8524880 SAREPTA THERAPS INC Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Apr, 2026

(1 year, 8 months from now)

US9228187 SAREPTA THERAPS INC Antisense molecules and methods for treating pathologies
Nov, 2030

(6 years from now)

US10287586 SAREPTA THERAPS INC Antisense molecules and methods for treating pathologies
Nov, 2030

(6 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10533174 SAREPTA THERAPS INC Splice-region antisense composition and method
May, 2021

(3 years ago)

US10781450 SAREPTA THERAPS INC Antisense molecules and methods for treating pathologies
Nov, 2030

(6 years from now)

US9758783 SAREPTA THERAPS INC Antisense molecules and methods for treating pathologies
Nov, 2030

(6 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Feb 25, 2026
Orphan Drug Exclusivity(ODE-347) Feb 25, 2028

Drugs and Companies using CASIMERSEN ingredient

NCE-1 date: 25 February, 2025

Market Authorisation Date: 25 February, 2021

Treatment: Treatment of duchenne muscular dystrophy (dmd) in patients who have a mutation of the dmd gene that is amenable to exon 45 skipping by restoring an mrna reading frame to induce dystrophin protein prod...

Dosage: SOLUTION

More Information on Dosage

AMONDYS 45 family patents

Family Patents

2. Apretude patent expiration

APRETUDE's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8410103 VIIV HLTHCARE (3S,11aR)-N-[2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide useful as anti-HIV agent
Apr, 2026

(1 year, 9 months from now)

US10927129 VIIV HLTHCARE N-[(2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3] oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide having HIV integrase inhibitory activity
Apr, 2026

(1 year, 9 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11224597 VIIV HLTHCARE Pharmaceutical compositions
Sep, 2031

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jan 21, 2026

Drugs and Companies using CABOTEGRAVIR ingredient

NCE-1 date: 21 January, 2025

Market Authorisation Date: 20 December, 2021

Treatment: NA

Dosage: SUSPENSION, EXTENDED RELEASE

More Information on Dosage

APRETUDE family patents

Family Patents

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

3. Azstarys patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10584112 COMMAVE THERAP Methylphenidate-prodrugs, processes of making and using the same
Dec, 2037

(13 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9079928 COMMAVE THERAP Methylphenidate-oxoacid conjugates, processes of making and using the same
Jul, 2032

(8 years from now)

US10759778 COMMAVE THERAP Methylphenidate-prodrugs, processes of making and using the same
Dec, 2037

(13 years from now)

US10954213 COMMAVE THERAP Compositions comprising methylphenidate-prodrugs, processes of making and using the same
Dec, 2037

(13 years from now)

US10858341 COMMAVE THERAP Compositions comprising methylphenidate-prodrugs, processes of making and using the same
Dec, 2037

(13 years from now)

US10584113 COMMAVE THERAP Methylphenidate-prodrugs, processes of making and using the same
Dec, 2037

(13 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 07, 2026

Drugs and Companies using DEXMETHYLPHENIDATE HYDROCHLORIDE; SERDEXMETHYLPHENIDATE CHLORIDE ingredient

NCE-1 date: 07 May, 2025

Market Authorisation Date: 07 May, 2021

Treatment: Treatment of attention-deficit hyperactivity disorder (adhd) with serdexmethylphenidate and dexmethylphenidate

Dosage: CAPSULE

More Information on Dosage

AZSTARYS family patents

Family Patents

4. Breo Ellipta patent expiration

BREO ELLIPTA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7101866 GLAXO GRP LTD Anti-inflammatory androstane derivative
Aug, 2021

(2 years ago)

USRE44874 GLAXO GRP LTD Phenethanolamine derivatives for treatment of respiratory diseases
Mar, 2023

(1 year, 3 months ago)

US7439393 GLAXO GRP LTD Phenethanolamine derivatives for treatment of respiratory diseases
May, 2025

(10 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5873360 GLAXO GRP LTD Inhalation device
Feb, 2016

(8 years ago)

US7101866 GLAXO GRP LTD Anti-inflammatory androstane derivative
Aug, 2021

(2 years ago)

US6878698 GLAXO GRP LTD Anti-inflammatory androstane derivatives
Aug, 2021

(2 years ago)

US6537983 GLAXO GRP LTD Anti-inflammatory androstane derivatives
Aug, 2021

(2 years ago)

US7629335 GLAXO GRP LTD Anti-inflammatory androstane derivative
Aug, 2021

(2 years ago)

US6759398 GLAXO GRP LTD Anti-inflammatory androstane derivative
Aug, 2021

(2 years ago)

US7776895 GLAXO GRP LTD Inhalation devices for delivering phenethanolamine derivatives for the treatment of respiratory diseases
Sep, 2022

(1 year, 10 months ago)

US7361787 GLAXO GRP LTD Phenethanolamine derivatives for treatment of respiratory diseases
Mar, 2023

(1 year, 3 months ago)

US7439393

(Pediatric)

GLAXO GRP LTD Phenethanolamine derivatives for treatment of respiratory diseases
Nov, 2025

(1 year, 4 months from now)

US8511304 GLAXO GRP LTD Medicament dispenser
Jun, 2027

(2 years from now)

US9333310 GLAXO GRP LTD Medicament dispenser
Oct, 2027

(3 years from now)

US8113199 GLAXO GRP LTD Counter for use with a medicament dispenser
Oct, 2027

(3 years from now)

US8511304

(Pediatric)

GLAXO GRP LTD Medicament dispenser
Dec, 2027

(3 years from now)

US8161968 GLAXO GRP LTD Medicament dispenser
Feb, 2028

(3 years from now)

US9333310

(Pediatric)

GLAXO GRP LTD Medicament dispenser
Apr, 2028

(3 years from now)

US8113199

(Pediatric)

GLAXO GRP LTD Counter for use with a medicament dispenser
Apr, 2028

(3 years from now)

US8161968

(Pediatric)

GLAXO GRP LTD Medicament dispenser
Aug, 2028

(4 years from now)

US11116721 GLAXO GRP LTD Pharmaceutical formulations comprising 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl) phenol
Feb, 2029

(4 years from now)

US11116721

(Pediatric)

GLAXO GRP LTD Pharmaceutical formulations comprising 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl) phenol
Aug, 2029

(5 years from now)

US8534281 GLAXO GRP LTD Manifold for use in medicament dispenser
Mar, 2030

(5 years from now)

US8534281

(Pediatric)

GLAXO GRP LTD Manifold for use in medicament dispenser
Sep, 2030

(6 years from now)

US8746242 GLAXO GRP LTD Medicament dispenser
Oct, 2030

(6 years from now)

US8746242

(Pediatric)

GLAXO GRP LTD Medicament dispenser
Apr, 2031

(6 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Apr 30, 2018
New Indication(I-708) Apr 30, 2018
New Chemical Entity Exclusivity(NCE) May 10, 2018
M(M-202) May 15, 2020
New Patient Population(NPP) May 13, 2026
New Strength(NS) May 13, 2026
Pediatric Exclusivity(PED) Nov 13, 2026

Drugs and Companies using FLUTICASONE FUROATE; VILANTEROL TRIFENATATE ingredient

NCE-1 date: 13 November, 2025

Market Authorisation Date: 12 May, 2023

Treatment: Indicated for long-term, once-daily maintenance treatment of airflow obstruction in pts with copd, including chronic bronchitis and/or emphysema, also to reduce exacerbations of copd in pts with a his...

Dosage: POWDER

More Information on Dosage

BREO ELLIPTA family patents

Family Patents

5. Bylvay patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7132416 IPSEN Benzothiazepine and benzothiazepine derivatives with ileal bile acid transport (IBAT) inhibotory activity for the treatment hyperlipidaemia
Sep, 2022

(1 year, 10 months ago)

US10975046 IPSEN Crystal modifications of odevixibat
Jun, 2039

(14 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9694018 IPSEN IBAT inhibitors for the treatment of liver disease
Nov, 2031

(7 years from now)

US10093697 IPSEN IBAT inhibitors for the treatment of liver diseases
Nov, 2031

(7 years from now)

US10011633 IPSEN IBAT inhibitors for the treatment of liver diseases
Nov, 2031

(7 years from now)

US10487111 IPSEN IBAT inhibitors for the treatment of liver diseases
Nov, 2031

(7 years from now)

US10981952 IPSEN IBAT inhibitors for the treatment of liver diseases
Nov, 2031

(7 years from now)

US11732006 IPSEN IBAT inhibitors for the treatment of liver diseases
Nov, 2031

(7 years from now)

US11365182 IPSEN Crystal modifications of odevixibat
Jun, 2039

(14 years from now)

US11801226 IPSEN Pharmaceutical formulation of odevixibat
Jun, 2039

(14 years from now)

US11802115 IPSEN Pharmaceutical formulation of odevixibat
Jun, 2039

(14 years from now)

US11583539 IPSEN Treating progressive familial intrahepatic cholestasis (PFIC) with IBAT inhibitors
Nov, 2041

(17 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-918) Jun 13, 2026
New Chemical Entity Exclusivity(NCE) Jul 20, 2026
Orphan Drug Exclusivity(ODE-363) Jul 20, 2028
Orphan Drug Exclusivity(ODE-436) Jun 13, 2030

Drugs and Companies using ODEVIXIBAT ingredient

NCE-1 date: 20 July, 2025

Market Authorisation Date: 20 July, 2021

Treatment: Method of treating cholestatic pruritus in patients 12 months or older suffering from alagille syndrome (algs); Method of reducing serum bile acids in patients 12 months or older suffering from alagil...

Dosage: CAPSULE, PELLETS; CAPSULE

More Information on Dosage

BYLVAY family patents

Family Patents

6. Cabenuva Kit patent expiration

CABENUVA KIT's oppositions filed in EPO
CABENUVA KIT IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6838464 VIIV HLTHCARE 2,4-Di(hetero-)arylamino(-oxy)-5-substituted pyrimidines as antineaoplastic agents
Feb, 2021

(3 years ago)

US8080551 VIIV HLTHCARE HIV inhibiting pyrimidines derivatives
Apr, 2023

(1 year, 3 months ago)

US7125879 VIIV HLTHCARE HIV inhibiting pyrimidines derivatives
Apr, 2025

(9 months from now)

US8410103 VIIV HLTHCARE (3S,11aR)-N-[2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide useful as anti-HIV agent
Apr, 2026

(1 year, 9 months from now)

US10927129 VIIV HLTHCARE N-[(2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3] oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide having HIV integrase inhibitory activity
Apr, 2026

(1 year, 9 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11389447 VIIV HLTHCARE Aqueous suspensions of TMC278
Jun, 2027

(2 years from now)

US11224597 VIIV HLTHCARE Pharmaceutical compositions
Sep, 2031

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Dosing Schedule(D-184) Jan 31, 2025
New Patient Population(NPP) Mar 29, 2025
New Chemical Entity Exclusivity(NCE) Jan 21, 2026

Drugs and Companies using CABOTEGRAVIR; RILPIVIRINE ingredient

NCE-1 date: 21 January, 2025

Market Authorisation Date: 21 January, 2021

Treatment: Treatment of hiv-1 infection in adults and adolescents 12 years of age and older and weighing at least 35 kg by monthly administration of rilpivirine suspension as part of combination therapy; Treatme...

Dosage: SUSPENSION, EXTENDED RELEASE

More Information on Dosage

CABENUVA KIT family patents

Family Patents

7. Corlanor patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7879842 AMGEN INC Beta-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
Feb, 2026

(1 year, 7 months from now)

US7361650 AMGEN INC γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
Feb, 2026

(1 year, 7 months from now)

US7361649 AMGEN INC β-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
Feb, 2026

(1 year, 7 months from now)

US7867996 AMGEN INC γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
Dec, 2026

(2 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Apr 15, 2020
New Product(NP) Apr 22, 2022
Orphan Drug Exclusivity(ODE-234) Apr 22, 2026
Pediatric Exclusivity(PED) Oct 22, 2026

Drugs and Companies using IVABRADINE ingredient

NCE-1 date: 22 October, 2025

Market Authorisation Date: 22 April, 2019

Treatment: A method for treating heart failure in a human using a crystalline form of ivabradine hydrochloride

Dosage: SOLUTION

More Information on Dosage

CORLANOR family patents

Family Patents

8. Cosela patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8598197 G1 THERAP CDK inhibitors
Oct, 2031

(7 years from now)

US10189849 G1 THERAP CDK inhibitors
Oct, 2031

(7 years from now)

US8598186 G1 THERAP CDK inhibitors
Oct, 2031

(7 years from now)

US9957276 G1 THERAP CDK inhibitors
Oct, 2031

(7 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10927120 G1 THERAP CDK inhibitors
Oct, 2031

(7 years from now)

US10189850 G1 THERAP CDK inhibitors
Oct, 2031

(7 years from now)

US10085992 G1 THERAP Transient protection of normal cells during chemotherapy
Mar, 2034

(9 years from now)

US10966984 G1 THERAP Transient protection of normal cells during chemotherapy
Mar, 2034

(9 years from now)

US9487530 G1 THERAP Transient protection of normal cells during chemotherapy
Mar, 2034

(9 years from now)

US11717523 G1 THERAP Transient protection of normal cells during chemotherapy
Mar, 2034

(9 years from now)

US11040042 G1 THERAP Transient protection of normal cells during chemotherapy
Mar, 2034

(9 years from now)

US11529352 G1 THERAP Preservation of immune response during chemotherapy regimens
Jul, 2039

(15 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Feb 12, 2026

Drugs and Companies using TRILACICLIB DIHYDROCHLORIDE ingredient

NCE-1 date: 12 February, 2025

Market Authorisation Date: 12 February, 2021

Treatment: A method to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a carboplatin and etoposide-containing regimen for extensive-stage small cell l...

Dosage: POWDER

More Information on Dosage

COSELA family patents

Family Patents

9. Cotellic patent expiration

COTELLIC's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7803839 GENENTECH INC Azetidines as MEK inhibitors for the treatment of proliferative diseases
Nov, 2029

(5 years from now)

US10478400 GENENTECH INC Immediate-release tablets containing combimetinib and methods of making and using the same
Jun, 2036

(11 years from now)

US11254649 GENENTECH INC Crystalline fumarate salt of (S)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl]-methanone
Jun, 2036

(11 years from now)

US10590102 GENENTECH INC Crystalline fumarate salt of (S)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl]methanone
Jun, 2036

(11 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8362002 GENENTECH INC Azetidines as MEK inhibitors for the treatment of proliferative diseases
Oct, 2026

(2 years from now)

US11597699 GENENTECH INC MEK inhibitors and methods of their use
Oct, 2026

(2 years from now)

US8362002

(Pediatric)

GENENTECH INC Azetidines as MEK inhibitors for the treatment of proliferative diseases
Apr, 2027

(2 years from now)

US7803839

(Pediatric)

GENENTECH INC Azetidines as MEK inhibitors for the treatment of proliferative diseases
May, 2030

(5 years from now)

US11087354 GENENTECH INC Combination therapies
Jun, 2034

(9 years from now)

US11087354

(Pediatric)

GENENTECH INC Combination therapies
Dec, 2034

(10 years from now)

US10478400

(Pediatric)

GENENTECH INC Immediate-release tablets containing combimetinib and methods of making and using the same
Dec, 2036

(12 years from now)

US11254649

(Pediatric)

GENENTECH INC Crystalline fumarate salt of (S)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl]-methanone
Dec, 2036

(12 years from now)

US10590102

(Pediatric)

GENENTECH INC Crystalline fumarate salt of (S)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl]methanone
Dec, 2036

(12 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Nov 10, 2020
Orphan Drug Exclusivity(ODE) Nov 10, 2022
Orphan Drug Exclusivity(ODE-101) Nov 10, 2022
M(M-278) Jul 28, 2025
New Indication(I-902) Oct 28, 2025
Pediatric Exclusivity(PED) Jan 28, 2026
Orphan Drug Exclusivity(ODE-416) Oct 28, 2029

Drugs and Companies using COBIMETINIB FUMARATE ingredient

NCE-1 date: 28 January, 2025

Market Authorisation Date: 10 November, 2015

Treatment: Method of using cobimetinib for the treatment of melanoma; As a single agent for the treatment of adult patients with histiocytic neoplasms

Dosage: TABLET

More Information on Dosage

COTELLIC family patents

Family Patents

10. Cytalux patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9341629 ON TARGET LABS Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors
Aug, 2033

(9 years from now)

US10881747 ON TARGET LABS Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors
Aug, 2033

(9 years from now)

US9061057 ON TARGET LABS Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors
Aug, 2033

(9 years from now)

US9789208 ON TARGET LABS Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors
Aug, 2033

(9 years from now)

US9333270 ON TARGET LABS Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors
Aug, 2033

(9 years from now)

US9254341 ON TARGET LABS Methods of manufacture of pteroyl-amino acid-fluorescent dyes
Oct, 2033

(9 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-905) Dec 16, 2025
New Chemical Entity Exclusivity(NCE) Nov 29, 2026
Orphan Drug Exclusivity(ODE-390) Nov 29, 2028

Drugs and Companies using PAFOLACIANINE SODIUM ingredient

NCE-1 date: 29 November, 2025

Market Authorisation Date: 29 November, 2021

Treatment: Cytalux is an optical imaging agent indicated in adult patients with ovarian cancer as an adjunct for intraoperative identification of malignant lesions

Dosage: SOLUTION

More Information on Dosage

CYTALUX family patents

Family Patents

11. Empaveli patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9169307 APELLIS PHARMS Potent compstatin analogs
Nov, 2027

(3 years from now)

US7989589 APELLIS PHARMS Compstatin analogs with improved activity
Dec, 2027

(3 years from now)

US7888323 APELLIS PHARMS Potent compstatin analogs
Dec, 2027

(3 years from now)

US11661441 APELLIS PHARMS Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof
Jan, 2033

(8 years from now)

US10125171 APELLIS PHARMS Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof
Aug, 2033

(9 years from now)

US10035822 APELLIS PHARMS Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods
Nov, 2033

(9 years from now)

US11292815 APELLIS PHARMS Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods
Nov, 2033

(9 years from now)

US10875893 APELLIS PHARMS Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods
Nov, 2033

(9 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11040107 APELLIS PHARMS Dosing regimens and related compositions and methods
Apr, 2038

(13 years from now)

US11844841 APELLIS PHARMS Dosing regimens and related compositions and methods
Dec, 2038

(14 years from now)




Drug Exclusivity Drug Exclusivity Expiration
M(M-288) Feb 08, 2026
New Chemical Entity Exclusivity(NCE) May 14, 2026
Orphan Drug Exclusivity(ODE-351) May 14, 2028

Drugs and Companies using PEGCETACOPLAN ingredient

NCE-1 date: 14 May, 2025

Market Authorisation Date: 14 May, 2021

Treatment: Treatment of adult patients with paroxysmal nocturnal hemoglobinuria (pnh) by administration of 1080 mg of pegcetacoplan twice weekly; Treatment of adult patients with paroxysmal nocturnal hemoglobinu...

Dosage: SOLUTION

More Information on Dosage

EMPAVELI family patents

Family Patents

12. Exkivity patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10227342 TAKEDA PHARMS USA Heteroaryl compounds for kinase inhibition
May, 2035

(10 years from now)

US9796712 TAKEDA PHARMS USA Heteroaryl compounds for kinase inhibition
May, 2035

(10 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Sep 15, 2026
Orphan Drug Exclusivity(ODE-374) Sep 15, 2028

Drugs and Companies using MOBOCERTINIB SUCCINATE ingredient

NCE-1 date: 15 September, 2025

Market Authorisation Date: 15 September, 2021

Treatment: Treatment of patients with non-small cell lung cancer (nsclc) with epidermal growth factor receptor (egfr) exon 20 exon insertion mutations whose disease has progressed on or after platinum-based chem...

Dosage: CAPSULE

More Information on Dosage

EXKIVITY family patents

Family Patents

13. Farxiga patent expiration

FARXIGA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6414126 ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method
Oct, 2020

(3 years ago)

US6515117 ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method
Oct, 2025

(1 year, 2 months from now)

US7919598 ASTRAZENECA AB Crystal structures of SGLT2 inhibitors and processes for preparing same
Dec, 2029

(5 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6936590 ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method
Oct, 2020

(3 years ago)

US9198925 ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor
Oct, 2020

(3 years ago)

US9238076 ASTRAZENECA AB Polymer-based sustained release device
Apr, 2024

(2 months ago)

US8461105 ASTRAZENECA AB Polymer-based sustained release device
Apr, 2025

(8 months from now)

US8431685 ASTRAZENECA AB Polymer-based sustained release device
Apr, 2025

(8 months from now)

US7456254 ASTRAZENECA AB Polymer-based sustained release device
Jun, 2025

(11 months from now)

US8329648 ASTRAZENECA AB Methods for treating diabetes and reducing body weight
Aug, 2026

(2 years from now)

US8906851 ASTRAZENECA AB Method for treating diabetes
Aug, 2026

(2 years from now)

US8501698 ASTRAZENECA AB Crystal structures of SGLT2 inhibitors and processes for preparing same
Jun, 2027

(2 years from now)

US8716251 ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor
Mar, 2028

(3 years from now)

US8361972 ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor
Mar, 2028

(3 years from now)

US8221786 ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor
Mar, 2028

(3 years from now)

US7851502 ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor
Aug, 2028

(4 years from now)

US8721615 ASTRAZENECA AB Ampoule comprising an ampoule holder
Jan, 2030

(5 years from now)

US8685934 ASTRAZENECA AB Methods for treating extreme insulin resistance in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof
May, 2030

(5 years from now)

US11826376 ASTRAZENECA AB Methods of treating heart failure with preserved ejection fraction employing dapagliflozin and compositions comprising the same
Jul, 2039

(15 years from now)

US10973836 ASTRAZENECA AB Methods of treating heart failure with reduced ejection fraction
Mar, 2040

(15 years from now)

US11903955 ASTRAZENECA AB Methods of treating heart failure with reduced ejection fraction
Mar, 2040

(15 years from now)




Drug Exclusivity Drug Exclusivity Expiration
M(M-157) Mar 11, 2018
New Chemical Entity Exclusivity(NCE) Jan 08, 2019
M(M-212) Oct 20, 2020
M(M-238) Feb 22, 2022
New Indication(I-841) Oct 18, 2022
New Indication(I-834) May 05, 2023
New Indication(I-857) Apr 30, 2024
M(M-298) May 08, 2026
Pediatric Exclusivity(PED) Nov 08, 2026

Drugs and Companies using DAPAGLIFLOZIN ingredient

NCE-1 date: 08 November, 2025

Market Authorisation Date: 08 January, 2014

Treatment: Treatment of type 2 diabetes mellitus; Treatment of type 2 diabetes mellitus in combination with exenatide; Reducing hba1c in a human in need thereof in combination with a sustained-release compositio...

Dosage: TABLET

How can I launch a generic of FARXIGA before it's drug patent expiration?
More Information on Dosage

FARXIGA family patents

Family Patents

14. Fotivda patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7166722 AVEO PHARMS N-{2-chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-n′-(5-methyl-3-isoxazolyl)urea salt in crystalline form
Nov, 2024

(4 months from now)

US6821987 AVEO PHARMS Quinoline derivatives and quinazoline derivatives having azolyl group
Apr, 2025

(9 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11504365 AVEO PHARMS Use of tivozanib to treat subjects with refractory cancer
Nov, 2039

(15 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Mar 10, 2026

Drugs and Companies using TIVOZANIB HYDROCHLORIDE ingredient

NCE-1 date: 10 March, 2025

Market Authorisation Date: 10 March, 2021

Treatment: Treatment of adults with moderate hepatic impairment and relapsed or refractory advanced renal cell carcinoma following two or more prior systemic anti-cancer therapies with 1mg tivozanib hcl orally f...

Dosage: CAPSULE

More Information on Dosage

FOTIVDA family patents

Family Patents

15. Halaven patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6214865 EISAI INC Macrocyclic analogs and methods of their use and preparation
Jun, 2019

(5 years ago)

US7470720 EISAI INC Methods and compositions for use in treating cancer
Jun, 2019

(5 years ago)

US6469182 EISAI INC Intermediates in the preparation of macrocyclic analogs
Jun, 2019

(5 years ago)

US8097648 EISAI INC Methods and compositions for use in treating cancer
Jan, 2021

(3 years ago)

US6214865

(Pediatric)

EISAI INC Macrocyclic analogs and methods of their use and preparation
Jan, 2024

(5 months ago)

USRE46965 EISAI INC Intermediates for the preparation of analogs of Halichondrin B
Jan, 2027

(2 years from now)

USRE46965

(Pediatric)

EISAI INC Intermediates for the preparation of analogs of Halichondrin B
Jul, 2027

(2 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Nov 15, 2015
New Indication(I-721) Jan 28, 2019
Orphan Drug Exclusivity(ODE) Jan 28, 2023
Orphan Drug Exclusivity(ODE-107) Jan 28, 2023
M(M-280) Sep 13, 2025
Pediatric Exclusivity(PED) Mar 13, 2026

Drugs and Companies using ERIBULIN MESYLATE ingredient

NCE-1 date: 13 March, 2025

Market Authorisation Date: 15 November, 2010

Treatment: Treatment of patients with metastatic breast cancer

Dosage: SOLUTION

How can I launch a generic of HALAVEN before it's drug patent expiration?
More Information on Dosage

HALAVEN family patents

Family Patents

16. Imbruvica patent expiration

IMBRUVICA's oppositions filed in EPO
IMBRUVICA IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8957079 PHARMACYCLICS LLC Inhibitors of Bruton's tyrosine kinase
Dec, 2026

(2 years from now)

US9181257 PHARMACYCLICS LLC Inhibitors of Bruton's tyrosine kinase
Dec, 2026

(2 years from now)

US7514444 PHARMACYCLICS LLC Inhibitors of bruton's tyrosine kinase
Dec, 2026

(2 years from now)

US8735403 PHARMACYCLICS LLC Inhibitors of Bruton's tyrosine kinase
Dec, 2026

(2 years from now)

US8697711 PHARMACYCLICS LLC Inhibitors of bruton'S tyrosine kinase
Dec, 2026

(2 years from now)

US8008309 PHARMACYCLICS LLC Inhibitors of bruton's tyrosine kinase
Nov, 2027

(3 years from now)

US9725455 PHARMACYCLICS LLC Crystalline forms of a bruton's tyrosine kinase inhibitor
Jun, 2033

(8 years from now)

US10125140 PHARMACYCLICS LLC Crystalline forms of a bruton's tyrosine kinase inhibitor
Jun, 2033

(8 years from now)

US10106548 PHARMACYCLICS LLC Crystalline forms of a Bruton's tyrosine kinase inhibitor
Jun, 2033

(8 years from now)

US9296753 PHARMACYCLICS LLC Crystalline forms of a Bruton's tyrosine kinase inhibitor
Oct, 2033

(9 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8476284 PHARMACYCLICS LLC Inhibitors of Bruton's tyrosine kinase
Dec, 2026

(2 years from now)

US8952015 PHARMACYCLICS LLC Inhibitors of Bruton's tyrosine kinase
Dec, 2026

(2 years from now)

US8497277 PHARMACYCLICS LLC Inhibitors of Bruton's tyrosine kinase
Dec, 2026

(2 years from now)

US8703780 PHARMACYCLICS LLC Inhibitors of Bruton's tyrosine kinase
Dec, 2026

(2 years from now)

US8754091 PHARMACYCLICS LLC Inhibitors of bruton's tyrosine kinase
Dec, 2026

(2 years from now)

US8563563 PHARMACYCLICS LLC Inhibitors of bruton's tyrosine kinase
Apr, 2027

(2 years from now)

US7514444

(Pediatric)

PHARMACYCLICS LLC Inhibitors of bruton's tyrosine kinase
Jun, 2027

(2 years from now)

US8476284

(Pediatric)

PHARMACYCLICS LLC Inhibitors of Bruton's tyrosine kinase
Jun, 2027

(2 years from now)

US8497277

(Pediatric)

PHARMACYCLICS LLC Inhibitors of Bruton's tyrosine kinase
Jun, 2027

(2 years from now)

US8703780

(Pediatric)

PHARMACYCLICS LLC Inhibitors of Bruton's tyrosine kinase
Jun, 2027

(2 years from now)

US8735403

(Pediatric)

PHARMACYCLICS LLC Inhibitors of Bruton's tyrosine kinase
Jun, 2027

(2 years from now)

US8697711

(Pediatric)

PHARMACYCLICS LLC Inhibitors of bruton'S tyrosine kinase
Jun, 2027

(2 years from now)

US8754091

(Pediatric)

PHARMACYCLICS LLC Inhibitors of bruton's tyrosine kinase
Jun, 2027

(2 years from now)

US9181257

(Pediatric)

PHARMACYCLICS LLC Inhibitors of Bruton's tyrosine kinase
Jun, 2027

(2 years from now)

US8957079

(Pediatric)

PHARMACYCLICS LLC Inhibitors of Bruton's tyrosine kinase
Jun, 2027

(2 years from now)

US8952015

(Pediatric)

PHARMACYCLICS LLC Inhibitors of Bruton's tyrosine kinase
Jun, 2027

(2 years from now)

US8563563

(Pediatric)

PHARMACYCLICS LLC Inhibitors of bruton's tyrosine kinase
Oct, 2027

(3 years from now)

US8008309

(Pediatric)

PHARMACYCLICS LLC Inhibitors of bruton's tyrosine kinase
May, 2028

(3 years from now)

US10751342 PHARMACYCLICS LLC Use of inhibitors of Bruton's tyrosine kinase (Btk)
Jun, 2031

(6 years from now)

US9801883 PHARMACYCLICS LLC Use of inhibitors of bruton's tyrosine kinase (Btk)
Jun, 2031

(6 years from now)

US9125889 PHARMACYCLICS LLC Use of inhibitors of Bruton's tyrosine kinase (Btk)
Jun, 2031

(6 years from now)

US9814721 PHARMACYCLICS LLC Use of inhibitors of bruton'S tyrosine kinase (BTK)
Jun, 2031

(6 years from now)

US11672803 PHARMACYCLICS LLC Use of inhibitors of Brutons tyrosine kinase (Btk)
Jun, 2031

(6 years from now)

US10004746 PHARMACYCLICS LLC Use of inhibitors of Bruton's tyrosine kinase (Btk)
Jun, 2031

(6 years from now)

US10478439 PHARMACYCLICS LLC Use of inhibitors of bruton's tyrosine kinase (Btk)
Jun, 2031

(6 years from now)

US9801881 PHARMACYCLICS LLC Use of inhibitors of bruton's tyrosine kinase (BTK)
Jun, 2031

(6 years from now)

US10016435 PHARMACYCLICS LLC Use of inhibitors of Bruton's tyrosine kinase (Btk)
Jun, 2031

(6 years from now)

US8754090 PHARMACYCLICS LLC Use of inhibitors of bruton's tyrosine kinase (Btk)
Jun, 2031

(6 years from now)

US8999999 PHARMACYCLICS LLC Use of inhibitors of Bruton's tyrosine kinase (Btk)
Jun, 2031

(6 years from now)

US10653696 PHARMACYCLICS LLC Use of inhibitors of bruton's tyrosine kinase (BTK)
Jun, 2031

(6 years from now)

US9801883

(Pediatric)

PHARMACYCLICS LLC Use of inhibitors of bruton's tyrosine kinase (Btk)
Dec, 2031

(7 years from now)

US8999999

(Pediatric)

PHARMACYCLICS LLC Use of inhibitors of Bruton's tyrosine kinase (Btk)
Dec, 2031

(7 years from now)

US10653696

(Pediatric)

PHARMACYCLICS LLC Use of inhibitors of bruton's tyrosine kinase (BTK)
Dec, 2031

(7 years from now)

US10478439

(Pediatric)

PHARMACYCLICS LLC Use of inhibitors of bruton's tyrosine kinase (Btk)
Dec, 2031

(7 years from now)

US10751342

(Pediatric)

PHARMACYCLICS LLC Use of inhibitors of Bruton's tyrosine kinase (Btk)
Dec, 2031

(7 years from now)

US10004746

(Pediatric)

PHARMACYCLICS LLC Use of inhibitors of Bruton's tyrosine kinase (Btk)
Dec, 2031

(7 years from now)

US9125889

(Pediatric)

PHARMACYCLICS LLC Use of inhibitors of Bruton's tyrosine kinase (Btk)
Dec, 2031

(7 years from now)

US9801881

(Pediatric)

PHARMACYCLICS LLC Use of inhibitors of bruton's tyrosine kinase (BTK)
Dec, 2031

(7 years from now)

US9814721

(Pediatric)

PHARMACYCLICS LLC Use of inhibitors of bruton'S tyrosine kinase (BTK)
Dec, 2031

(7 years from now)

US8754090

(Pediatric)

PHARMACYCLICS LLC Use of inhibitors of bruton's tyrosine kinase (Btk)
Dec, 2031

(7 years from now)

US10016435

(Pediatric)

PHARMACYCLICS LLC Use of inhibitors of Bruton's tyrosine kinase (Btk)
Dec, 2031

(7 years from now)

US10961251 PHARMACYCLICS LLC Crystalline forms of a Bruton's tyrosine kinase inhibitor
Jun, 2033

(8 years from now)

US10294231 PHARMACYCLICS LLC Crystalline forms of a Bruton's tyrosine kinase inhibitor
Jun, 2033

(8 years from now)

US10752634 PHARMACYCLICS LLC Crystalline forms of a brutons tyrosine kinase inhibitor
Jun, 2033

(8 years from now)

US10294232 PHARMACYCLICS LLC Crystalline forms of a Bruton's tyrosine kinase inhibitor
Jun, 2033

(8 years from now)

US9713617 PHARMACYCLICS LLC Crystalline forms of a Bruton's tyrosine kinase inhibitor
Jun, 2033

(8 years from now)

US9540382 PHARMACYCLICS LLC Crystalline forms of a Bruton's tyrosine kinase inhibitor
Aug, 2033

(9 years from now)

US10294231

(Pediatric)

PHARMACYCLICS LLC Crystalline forms of a Bruton's tyrosine kinase inhibitor
Dec, 2033

(9 years from now)

US10106548

(Pediatric)

PHARMACYCLICS LLC Crystalline forms of a Bruton's tyrosine kinase inhibitor
Dec, 2033

(9 years from now)

US10294232

(Pediatric)

PHARMACYCLICS LLC Crystalline forms of a Bruton's tyrosine kinase inhibitor
Dec, 2033

(9 years from now)

US10961251

(Pediatric)

PHARMACYCLICS LLC Crystalline forms of a Bruton's tyrosine kinase inhibitor
Dec, 2033

(9 years from now)

US10752634

(Pediatric)

PHARMACYCLICS LLC Crystalline forms of a brutons tyrosine kinase inhibitor
Dec, 2033

(9 years from now)

US10125140

(Pediatric)

PHARMACYCLICS LLC Crystalline forms of a bruton's tyrosine kinase inhibitor
Dec, 2033

(9 years from now)

US9725455

(Pediatric)

PHARMACYCLICS LLC Crystalline forms of a bruton's tyrosine kinase inhibitor
Dec, 2033

(9 years from now)

US9713617

(Pediatric)

PHARMACYCLICS LLC Crystalline forms of a Bruton's tyrosine kinase inhibitor
Dec, 2033

(9 years from now)

US9540382

(Pediatric)

PHARMACYCLICS LLC Crystalline forms of a Bruton's tyrosine kinase inhibitor
Feb, 2034

(9 years from now)

US9296753

(Pediatric)

PHARMACYCLICS LLC Crystalline forms of a Bruton's tyrosine kinase inhibitor
Apr, 2034

(9 years from now)

US9795604 PHARMACYCLICS LLC Methods of treating and preventing graft versus host disease
Oct, 2034

(10 years from now)

US10463668 PHARMACYCLICS LLC Methods of treating and preventing graft versus host disease
Oct, 2034

(10 years from now)

US10695350 PHARMACYCLICS LLC Methods of treating and preventing graft versus host disease
Oct, 2034

(10 years from now)

US10463668

(Pediatric)

PHARMACYCLICS LLC Methods of treating and preventing graft versus host disease
Apr, 2035

(10 years from now)

US9795604

(Pediatric)

PHARMACYCLICS LLC Methods of treating and preventing graft versus host disease
Apr, 2035

(10 years from now)

US10695350

(Pediatric)

PHARMACYCLICS LLC Methods of treating and preventing graft versus host disease
Apr, 2035

(10 years from now)

US10010507 PHARMACYCLICS LLC Pharmaceutical formulations of a bruton's tyrosine kinase inhibitor
Mar, 2036

(11 years from now)

US10213386 PHARMACYCLICS LLC Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor
Mar, 2036

(11 years from now)

US10828259 PHARMACYCLICS LLC Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor
Mar, 2036

(11 years from now)

US9655857 PHARMACYCLICS LLC Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor
Mar, 2036

(11 years from now)

US10010507

(Pediatric)

PHARMACYCLICS LLC Pharmaceutical formulations of a bruton's tyrosine kinase inhibitor
Sep, 2036

(12 years from now)

US9655857

(Pediatric)

PHARMACYCLICS LLC Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor
Sep, 2036

(12 years from now)

US10213386

(Pediatric)

PHARMACYCLICS LLC Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor
Sep, 2036

(12 years from now)

US10828259

(Pediatric)

PHARMACYCLICS LLC Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor
Sep, 2036

(12 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Nov 13, 2018
New Dosing Schedule(D-176) Aug 24, 2021
M(M-236) Jan 25, 2022
ODE*(ODE*) Aug 02, 2024
New Patient Population(NPP) Aug 24, 2025
Pediatric Exclusivity(PED) Feb 24, 2026
Orphan Drug Exclusivity(ODE-405) Aug 24, 2029

Drugs and Companies using IBRUTINIB ingredient

NCE-1 date: 24 February, 2025

Market Authorisation Date: 16 February, 2018

Treatment: Treatment of waldenstrom's macroglobulinemia; Treatment of small lymphocytic lymphoma with 17p deletion; Treatment of chronic lymphocytic leukemia; Treatment of relapsed or refractory chronic lymphocy...

Dosage: TABLET; CAPSULE

How can I launch a generic of IMBRUVICA before it's drug patent expiration?
More Information on Dosage

IMBRUVICA family patents

Family Patents

17. Jardiance patent expiration

JARDIANCE's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7713938 BOEHRINGER INGELHEIM Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
Apr, 2027

(2 years from now)

US7579449 BOEHRINGER INGELHEIM Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
Aug, 2028

(4 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7713938

(Pediatric)

BOEHRINGER INGELHEIM Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
Oct, 2027

(3 years from now)

US7579449

(Pediatric)

BOEHRINGER INGELHEIM Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
Feb, 2029

(4 years from now)

US8551957 BOEHRINGER INGELHEIM Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate
Oct, 2029

(5 years from now)

US8551957

(Pediatric)

BOEHRINGER INGELHEIM Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate
Apr, 2030

(5 years from now)

US10406172 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Jun, 2030

(5 years from now)

US10258637 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Apr, 2034

(9 years from now)

US11813275 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Apr, 2034

(9 years from now)

US11090323 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Apr, 2034

(9 years from now)

US11833166 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Apr, 2034

(9 years from now)

US11666590 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Apr, 2034

(9 years from now)

US9949997 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
May, 2034

(9 years from now)

US9949998 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Jun, 2034

(9 years from now)

US10258637

(Pediatric)

BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Oct, 2034

(10 years from now)

US11090323

(Pediatric)

BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Oct, 2034

(10 years from now)

US9949997

(Pediatric)

BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Nov, 2034

(10 years from now)

US9949998

(Pediatric)

BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Dec, 2034

(10 years from now)




Drug Exclusivity Drug Exclusivity Expiration
M(M-161) Jun 26, 2018
M(M-159) Jun 26, 2018
M(M-160) Jun 26, 2018
M(M-174) Mar 18, 2019
New Chemical Entity Exclusivity(NCE) Aug 01, 2019
New Indication(I-739) Dec 02, 2019
New Indication(I-869) Aug 18, 2024
M(M-82) Feb 24, 2025
Pediatric Exclusivity(PED) Dec 20, 2026
New Patient Population(NPP) Jun 20, 2026
New Indication(I-922) Sep 21, 2026

Drugs and Companies using EMPAGLIFLOZIN ingredient

NCE-1 date: 20 December, 2025

Market Authorisation Date: 01 August, 2014

Treatment: Method of treating type 2 diabetes mellitus by administering linagliptin in combination with empagliflozin; Method of treating type 2 diabetes mellitus by administering linagliptin in combination with...

Dosage: TABLET

How can I launch a generic of JARDIANCE before it's drug patent expiration?
More Information on Dosage

JARDIANCE family patents

Family Patents

18. Jentadueto patent expiration

JENTADUETO's oppositions filed in EPO
JENTADUETO IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7407955 BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
May, 2025

(9 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6303661 BOEHRINGER INGELHEIM Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals
Apr, 2017

(7 years ago)

US7078381 BOEHRINGER INGELHEIM Method of regulating glucose metabolism, and reagents related thereto
Feb, 2019

(5 years ago)

US6890898 BOEHRINGER INGELHEIM Method of regulating glucose metabolism, and reagents related thereto
Feb, 2019

(5 years ago)

US7459428 BOEHRINGER INGELHEIM Method of regulating glucose metabolism, and reagents related thereto
Feb, 2019

(5 years ago)

US8178541 BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
Aug, 2023

(10 months ago)

US8119648 BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
Aug, 2023

(10 months ago)

US7407955

(Pediatric)

BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
Nov, 2025

(1 year, 3 months from now)

US8883805 BOEHRINGER INGELHEIM Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines
Nov, 2025

(1 year, 4 months from now)

US8883805

(Pediatric)

BOEHRINGER INGELHEIM Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines
May, 2026

(1 year, 10 months from now)

US8673927 BOEHRINGER INGELHEIM Uses of DPP-IV inhibitors
May, 2027

(2 years from now)

US9173859 BOEHRINGER INGELHEIM Uses of DPP IV inhibitors
May, 2027

(2 years from now)

US8673927

(Pediatric)

BOEHRINGER INGELHEIM Uses of DPP-IV inhibitors
Nov, 2027

(3 years from now)

US9415016 BOEHRINGER INGELHEIM DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
Apr, 2029

(4 years from now)

US10022379 BOEHRINGER INGELHEIM DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
Apr, 2029

(4 years from now)

US10973827 BOEHRINGER INGELHEIM DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
Apr, 2029

(4 years from now)

US10973827

(Pediatric)

BOEHRINGER INGELHEIM DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
Oct, 2029

(5 years from now)

US9415016

(Pediatric)

BOEHRINGER INGELHEIM DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
Oct, 2029

(5 years from now)

US10022379

(Pediatric)

BOEHRINGER INGELHEIM DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
Oct, 2029

(5 years from now)

US11911388 BOEHRINGER INGELHEIM Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug
Apr, 2030

(5 years from now)

US9155705 BOEHRINGER INGELHEIM DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
May, 2030

(5 years from now)

US8846695 BOEHRINGER INGELHEIM Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor
Jun, 2030

(5 years from now)

US9155705

(Pediatric)

BOEHRINGER INGELHEIM DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
Nov, 2030

(6 years from now)

US8846695

(Pediatric)

BOEHRINGER INGELHEIM Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor
Dec, 2030

(6 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Combination(NC) Jan 30, 2015
New Chemical Entity Exclusivity(NCE) May 02, 2016
M(M-146) Jul 30, 2017
M(M-258) Jul 03, 2022
M(M-252) Mar 30, 2023
M(M-295) Jun 20, 2026
Pediatric Exclusivity(PED) Dec 20, 2026

Drugs and Companies using LINAGLIPTIN; METFORMIN HYDROCHLORIDE ingredient

NCE-1 date: 20 December, 2025

Market Authorisation Date: 30 January, 2012

Treatment: Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor; Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-4 inhibitor in com...

Dosage: TABLET

How can I launch a generic of JENTADUETO before it's drug patent expiration?
More Information on Dosage

JENTADUETO family patents

Family Patents

19. Kerendia patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8436180 BAYER HLTHCARE Substituted-4-aryl-1,4-dihydro-1,6-naphthyridinamides and use thereof
Apr, 2029

(4 years from now)

USRE49826 BAYER HLTHCARE Method for the preparation of (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1-6-naphthyridine-3-carboxamide and the purification thereof for use as an active pharmaceutical ingredient
Jul, 2035

(11 years from now)




Drug Exclusivity Drug Exclusivity Expiration
M(M-279) Sep 01, 2025
New Chemical Entity Exclusivity(NCE) Jul 09, 2026

Drugs and Companies using FINERENONE ingredient

NCE-1 date: 09 July, 2025

Market Authorisation Date: 09 July, 2021

Treatment: NA

Dosage: TABLET

More Information on Dosage

KERENDIA family patents

Family Patents

20. Korsuva patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7402564 CARA THERAP Synthetic peptide amides
Nov, 2027

(3 years from now)

US8536131 CARA THERAP Synthetic peptide amides and dimers thereof
Nov, 2027

(3 years from now)

US10793596 CARA THERAP Synthetic peptide amides
Nov, 2027

(3 years from now)

US10017536 CARA THERAP Synthetic peptide amides and dimers thereof
Nov, 2027

(3 years from now)

US7727963 CARA THERAP Synthetic peptide amides
Nov, 2027

(3 years from now)

US7713937 CARA THERAP Synthetic peptide amides and dimeric forms thereof
Nov, 2027

(3 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10138270 CARA THERAP Synthetic peptide amides
Nov, 2027

(3 years from now)

US9359399 CARA THERAP Synthetic peptide amides
Nov, 2027

(3 years from now)

US9334305 CARA THERAP Synthetic peptide amides and dimers thereof
Nov, 2027

(3 years from now)

US8236766 CARA THERAP Uses of synthetic peptide amides
Nov, 2027

(3 years from now)

US8217007 CARA THERAP Synthetic peptide amides
Nov, 2027

(3 years from now)

US8486894 CARA THERAP Synthetic peptide amides and dimeric forms thereof
Nov, 2027

(3 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Aug 23, 2026

Drugs and Companies using DIFELIKEFALIN ACETATE ingredient

NCE-1 date: 23 August, 2025

Market Authorisation Date: 23 August, 2021

Treatment: Treatment of moderate-to-severe pruritus associated with chronic kidney disease (ckd-ap) in adults undergoing hemodialysis (hd)

Dosage: SOLUTION

More Information on Dosage

KORSUVA family patents

Family Patents

21. Lenvima patent expiration

LENVIMA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7253286 EISAI INC Nitrogen-containing aromatic derivatives
Oct, 2025

(1 year, 3 months from now)

US7612208 EISAI INC Crystalline form of the salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide or the solvate of the salt and a process for preparing the same
Sep, 2026

(2 years from now)

US10407393 EISAI INC High-purity quinoline derivative and method for manufacturing same
Aug, 2035

(11 years from now)

US11186547 EISAI INC High-purity quinoline derivative and method for manufacturing same
Aug, 2035

(11 years from now)

US10259791 EISAI INC High-purity quinoline derivative and method for manufacturing same
Aug, 2035

(11 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7253286

(Pediatric)

EISAI INC Nitrogen-containing aromatic derivatives
Apr, 2026

(1 year, 9 months from now)

US7612208

(Pediatric)

EISAI INC Crystalline form of the salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide or the solvate of the salt and a process for preparing the same
Mar, 2027

(2 years from now)

US9006256 EISAI INC Antitumor agent for thyroid cancer
Jul, 2027

(3 years from now)

US9006256

(Pediatric)

EISAI INC Antitumor agent for thyroid cancer
Jan, 2028

(3 years from now)

US11090386 EISAI INC Method for suppressing bitterness of quinoline derivative
Feb, 2036

(11 years from now)

US10259791

(Pediatric)

EISAI INC High-purity quinoline derivative and method for manufacturing same
Feb, 2036

(11 years from now)

US10407393

(Pediatric)

EISAI INC High-purity quinoline derivative and method for manufacturing same
Feb, 2036

(11 years from now)

US11186547

(Pediatric)

EISAI INC High-purity quinoline derivative and method for manufacturing same
Feb, 2036

(11 years from now)

US11090386

(Pediatric)

EISAI INC Method for suppressing bitterness of quinoline derivative
Aug, 2036

(12 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-734) May 13, 2019
New Chemical Entity Exclusivity(NCE) Feb 13, 2020
New Indication(I-787) Aug 15, 2021
Orphan Drug Exclusivity(ODE-87) Feb 13, 2022
Orphan Drug Exclusivity(ODE) Feb 13, 2022
New Indication(I-807) Sep 17, 2022
M(M-269) Jul 21, 2024
New Indication(I-868) Aug 10, 2024
M(M-272) Dec 19, 2024
Orphan Drug Exclusivity(ODE-196) Aug 15, 2025
Pediatric Exclusivity(PED) Feb 15, 2026

Drugs and Companies using LENVATINIB MESYLATE ingredient

NCE-1 date: 15 February, 2025

Market Authorisation Date: 13 February, 2015

Treatment: Method for treating thyroid carcinoma including differentiated thyroid cancer; Treatment with lenvima by administering lenvima as a suspension

Dosage: CAPSULE

How can I launch a generic of LENVIMA before it's drug patent expiration?
More Information on Dosage

LENVIMA family patents

Family Patents

22. Leqvio patent expiration

LEQVIO's oppositions filed in EPO
LEQVIO IPR and PTAB Proceedings
Can you believe LEQVIO received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9074213 NOVARTIS Compositions and methods for inhibiting expression of a target gene
Mar, 2022

(2 years ago)

US8546143 NOVARTIS Compositions and methods for inhibiting expression of a target gene
Apr, 2022

(2 years ago)

US8232383 NOVARTIS RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
Feb, 2023

(1 year, 4 months ago)

US11078485 NOVARTIS Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
Nov, 2023

(8 months ago)

US9708610 NOVARTIS Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
Jan, 2024

(6 months ago)

US10669544 NOVARTIS Therapeutic compositions
Mar, 2024

(4 months ago)

US9708615 NOVARTIS Therapeutic compositions
Mar, 2024

(4 months ago)

US10273477 NOVARTIS Therapeutic compositions
Mar, 2024

(4 months ago)

US11530408 NOVARTIS Therapeutic compositions
May, 2024

(a month ago)

US8809292 NOVARTIS Compositions and methods for inhibiting expression of the PCSK9 gene
May, 2027

(2 years from now)

US10131907 NOVARTIS Glycoconjugates of RNA interference agents
Aug, 2028

(4 years from now)

US10806791 NOVARTIS Carbohydrate conjugates as delivery agents for oligonucleotides
Dec, 2028

(4 years from now)

US9370582 NOVARTIS Carbohydrate conjugates as delivery agents for oligonucleotides
Dec, 2028

(4 years from now)

US8828956 NOVARTIS Carbohydrate conjugates as delivery agents for oligonucleotides
Dec, 2028

(4 years from now)

US8106022 NOVARTIS Carbohydrate conjugates as delivery agents for oligonucleotides
Dec, 2029

(5 years from now)

US10125369 NOVARTIS PCSK9 iRNA compositions and methods of use thereof
Aug, 2034

(10 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10590418 NOVARTIS Methods and compositions for RNAi mediated inhibition of gene expression in mammals
Jul, 2022

(1 year, 11 months ago)

US10266825 NOVARTIS Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
Nov, 2023

(8 months ago)

US8222222 NOVARTIS Compositions and methods for inhibiting expression of the PCSK9 gene
Dec, 2027

(3 years from now)

US10851377 NOVARTIS Methods and compositions for treating a proprotein convertase subtilisin kexin (PCSK9) gene-associated disorder
Aug, 2036

(12 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 22, 2026

Drugs and Companies using INCLISIRAN SODIUM ingredient

NCE-1 date: 22 December, 2025

Market Authorisation Date: 22 December, 2021

Treatment: As an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (hefh) or clinical atherosclerotic cardiovascular disease (ascv...

Dosage: SOLUTION

More Information on Dosage

LEQVIO family patents

Family Patents

23. Livmarli patent expiration

Can you believe LIVMARLI received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11260053 MIRUM Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
May, 2031

(6 years from now)

US11229661 MIRUM Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
Oct, 2032

(8 years from now)

US10512657 MIRUM Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
Oct, 2032

(8 years from now)

US11376251 MIRUM Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
Oct, 2032

(8 years from now)

US11229647 MIRUM Methods for treating cholestasis
Feb, 2040

(15 years from now)

US11918578 MIRUM Methods for treating cholestasis
Feb, 2040

(15 years from now)

US11497745 MIRUM Methods for treating cholestasis
Feb, 2040

(15 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Mar 13, 2026
New Chemical Entity Exclusivity(NCE) Sep 29, 2026
New Indication(I-938) Mar 13, 2027
Orphan Drug Exclusivity(ODE-379) Sep 29, 2028
Orphan Drug Exclusivity(ODE-429) Mar 13, 2030
Orphan Drug Exclusivity(ODE-471) Mar 13, 2031

Drugs and Companies using MARALIXIBAT CHLORIDE ingredient

NCE-1 date: 29 September, 2025

Market Authorisation Date: 29 September, 2021

Treatment: Treatment of cholestatic pruritus in patients with alagille syndrome (algs); Treatment of cholestatic pruritus in patients with progressive familial intrahepatic cholestatis (pfic)

Dosage: SOLUTION

More Information on Dosage

LIVMARLI family patents

Family Patents

24. Livtencity patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11684632 TAKEDA PHARMS USA Maribavir isomers, compositions, methods of making and methods of using
Jan, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Nov 23, 2026
Orphan Drug Exclusivity(ODE-388) Nov 23, 2028

Drugs and Companies using MARIBAVIR ingredient

NCE-1 date: 23 November, 2025

Market Authorisation Date: 23 November, 2021

Treatment: Treatment of patients with post-transplant cytomegalovirus (cmv) infection/disease refractory to treatment with ganciclovir, valganciclovir, cidofovir, or foscarnet, where the patient is a stem cell, ...

Dosage: TABLET

More Information on Dosage

LIVTENCITY family patents

Family Patents

25. Lumakras patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10519146 AMGEN INC KRAS G12C inhibitors and methods of using the same
May, 2038

(13 years from now)

US11827635 AMGEN INC Solid state forms
May, 2040

(15 years from now)

US11236091 AMGEN INC Solid state forms
May, 2040

(15 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11426404 AMGEN INC Dosing of KRAS inhibitor for treatment of cancers
Sep, 2040

(16 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 28, 2026
Orphan Drug Exclusivity(ODE-352) May 28, 2028

Drugs and Companies using SOTORASIB ingredient

NCE-1 date: 28 May, 2025

Market Authorisation Date: 28 May, 2021

Treatment: Treatment of adult patients with kras g12c-mutated locally advanced or metastatic non-small cell lung cancer (nsclc), as determined by an fda-approved test, who have received at least one prior system...

Dosage: TABLET

More Information on Dosage

LUMAKRAS family patents

Family Patents

26. Lupkynis patent expiration

LUPKYNIS IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7332472 AURINIA Cyclosporine analogue mixtures and their use as immunomodulating agents
Oct, 2024

(3 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11622991 AURINIA Protocol for treatment of lupus nephritis
Dec, 2037

(13 years from now)

US10286036 AURINIA Protocol for treatment of lupus nephritis
Dec, 2037

(13 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jan 22, 2026

Drugs and Companies using VOCLOSPORIN ingredient

NCE-1 date: 22 January, 2025

Market Authorisation Date: 22 January, 2021

Treatment: Treatment of patients with active lupus nephritis

Dosage: CAPSULE

More Information on Dosage

LUPKYNIS family patents

Family Patents

27. Lybalvi patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7956187 ALKERMES INC Method for decreasing opioid metabolism
Oct, 2021

(2 years ago)

US8252929 ALKERMES INC 8-carboxamido-2,6-methano-3-benzazocines
Oct, 2021

(2 years ago)

US7262298 ALKERMES INC 4-hydroxybenzomorphans
Nov, 2025

(1 year, 4 months from now)

US9119848 ALKERMES INC Morphinan derivatives for the treatment of drug overdose
Aug, 2031

(7 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10716785 ALKERMES INC Methods for treating antipsychotic-induced weight gain
Aug, 2031

(7 years from now)

US9126977 ALKERMES INC Methods for treating antipsychotic-induced weight gain
Aug, 2031

(7 years from now)

US9517235 ALKERMES INC Methods for treating antipsychotic-induced weight gain
Aug, 2031

(7 years from now)

US11185541 ALKERMES INC Methods for treating antipsychotic-induced weight gain
Aug, 2031

(7 years from now)

US11241425 ALKERMES INC Composition for treating mental illness
Aug, 2031

(7 years from now)

US11793805 ALKERMES INC Methods for treating antipsychotic-induced weight gain
Aug, 2031

(7 years from now)

US10300054 ALKERMES INC Methods for treating antipsychotic-induced weight gain
Aug, 2031

(7 years from now)

US11351166 ALKERMES INC Methods for treating antipsychotic-induced weight gain
Aug, 2031

(7 years from now)

US8778960 ALKERMES INC Methods for treating antipsychotic-induced weight gain
Feb, 2032

(7 years from now)

US11951111 ALKERMES INC Immediate release multilayer tablet
Nov, 2041

(17 years from now)

US11707466 ALKERMES INC Immediate release multilayer tablet
Nov, 2041

(17 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 28, 2026

Drugs and Companies using OLANZAPINE; SAMIDORPHAN L-MALATE ingredient

NCE-1 date: 28 May, 2025

Market Authorisation Date: 28 May, 2021

Treatment: Method of treating bipolar disorder by administering the atypical antipsychotic olanzapine and samidorphan, with reduced antipsychotic induced weight gain; Method of treating schizophrenia by administ...

Dosage: TABLET

More Information on Dosage

LYBALVI family patents

Family Patents

28. Nextstellis patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7732430 MAYNE PHARMA Drug delivery system comprising a tetrahydroxilated estrogen for use in hormonal contraception
Mar, 2025

(7 months from now)

US11793760 MAYNE PHARMA Orodispersible dosage unit containing an estetrol component
Jun, 2036

(11 years from now)

US11964055 MAYNE PHARMA Orodispersible dosage unit containing an estetrol component
Jun, 2036

(11 years from now)

US11957694 MAYNE PHARMA Orodispersible dosage unit containing an estetrol component
Jun, 2036

(11 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Apr 15, 2026

Drugs and Companies using DROSPIRENONE; ESTETROL ingredient

NCE-1 date: 15 April, 2025

Market Authorisation Date: 15 April, 2021

Treatment: Use by females of reproductive potential to prevent pregnancy

Dosage: TABLET

More Information on Dosage

NEXTSTELLIS family patents

Family Patents

29. Nulibry patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7504095 SENTYNL THERAPS INC Method for obtaining precursor Z and use thereof for the production of a means for therapy of human molybdenum cofactor deficiency
Jan, 2025

(6 months from now)




Drug Exclusivity Drug Exclusivity Expiration
M(M-286) Oct 27, 2025
New Chemical Entity Exclusivity(NCE) Feb 26, 2026
Orphan Drug Exclusivity(ODE-342) Feb 26, 2028

Drugs and Companies using FOSDENOPTERIN HYDROBROMIDE ingredient

NCE-1 date: 26 February, 2025

Market Authorisation Date: 26 February, 2021

Treatment: Method of treating molybdenum cofactor deficiency type a

Dosage: POWDER

More Information on Dosage

NULIBRY family patents

Family Patents

30. Pepaxto patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6992207 ONCOPEPTIDES AB Melphalan derivatives and their use as cancer chemotherapeutic drugs
Jun, 2024

(17 days ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10322182 ONCOPEPTIDES AB Lyophilized preparation of cytotoxic dipeptides
Apr, 2032

(7 years from now)

US10543274 ONCOPEPTIDES AB Lyophilized preparation of cytotoxic dipeptides
Apr, 2032

(7 years from now)

US10869928 ONCOPEPTIDES AB Lyophilized preparation of cytotoxic dipeptides
Apr, 2032

(7 years from now)

US10285946 ONCOPEPTIDES AB Lyophilized preparations of melphalan flufenamide
Apr, 2032

(7 years from now)

US11344622 ONCOPEPTIDES AB Lyophilized preparation of cytotoxic dipeptides
Apr, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Feb 26, 2026
Orphan Drug Exclusivity(ODE-348) Feb 26, 2028

Drugs and Companies using MELPHALAN FLUFENAMIDE HYDROCHLORIDE ingredient

NCE-1 date: 26 February, 2025

Market Authorisation Date: 26 February, 2021

Treatment: In combination with dexamethasone to treat relapsed or refractory multiple myeloma (refactory to at least 1 proteasome inhibitor, 1 immunomodulatory agent, and 1 anti-cd38 mab) in adults who received ...

Dosage: POWDER

More Information on Dosage

PEPAXTO family patents

Family Patents

31. Ponvory patent expiration

PONVORY's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
USRE43728 JANSSEN PHARMS Thiazolidin-4-one derivatives
Nov, 2024

(4 months from now)

US9062014 JANSSEN PHARMS Crystalline forms of (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-0-tolyl-thiazolidin-4-one
May, 2032

(7 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9000018 JANSSEN PHARMS Thiazolidin-4-one-derivatives
Nov, 2024

(4 months from now)

US8273779 JANSSEN PHARMS Thiazolidin 4-one derivatives
Dec, 2025

(1 year, 5 months from now)

US10220023 JANSSEN PHARMS Dosing regimen for a selective S1P1 receptor agonist
Dec, 2035

(11 years from now)

US11951097 JANSSEN PHARMS Methods of treating multiple sclerosis
Oct, 2042

(18 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Mar 18, 2026

Drugs and Companies using PONESIMOD ingredient

NCE-1 date: 18 March, 2025

Market Authorisation Date: 18 March, 2021

Treatment: Reduction of circulating lymphocytes in treating relapsing forms of multiple sclerosis (ms), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive dise...

Dosage: TABLET

More Information on Dosage

PONVORY family patents

Family Patents

32. Pylarify patent expiration

PYLARIFY's oppositions filed in EPO
Can you believe PYLARIFY received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8487129 PROGENICS PHARMS INC Heterodimers of glutamic acid
Nov, 2027

(3 years from now)

US9861713 PROGENICS PHARMS INC PSMA-binding agents and uses thereof
Jul, 2029

(5 years from now)

US8778305 PROGENICS PHARMS INC PSMA-binding agents and uses thereof
Sep, 2030

(6 years from now)

US11851407 PROGENICS PHARMS INC Synthesis of the radiolabeled prostate-specific membrane antigen (PSMA) inhibitor [18F]DCFPYL
Jun, 2037

(12 years from now)

US10947197 PROGENICS PHARMS INC Synthesis of the radiolabeled prostate-specific membrane antigen (PSMA) inhibitor [18F]DCFPyL
Jun, 2037

(12 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 26, 2026

Drugs and Companies using PIFLUFOLASTAT F-18 ingredient

NCE-1 date: 26 May, 2025

Market Authorisation Date: 26 May, 2021

Treatment: Method of positron emission tomography (pet) in men with prostate cancer

Dosage: SOLUTION

More Information on Dosage

PYLARIFY family patents

Family Patents

33. Qelbree patent expiration

QELBREE IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11324753 SUPERNUS PHARMS Method of treatment of attention deficit/hyperactivity disorder (ADHD)
Sep, 2029

(5 years from now)

US11458143 SUPERNUS PHARMS Method of treatment of attention deficit/hyperactivity disorder (ADHD)
Sep, 2029

(5 years from now)

US9662338 SUPERNUS PHARMS Formulations of viloxazine
Feb, 2033

(8 years from now)

US9358204 SUPERNUS PHARMS Formulations of viloxazine
Feb, 2033

(8 years from now)

US9603853 SUPERNUS PHARMS Formulations of viloxazine
Feb, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Apr 29, 2025
New Chemical Entity Exclusivity(NCE) Apr 02, 2026

Drugs and Companies using VILOXAZINE HYDROCHLORIDE ingredient

NCE-1 date: 02 April, 2025

Market Authorisation Date: 02 April, 2021

Treatment: For the treatment of attention deficit hyperactivity disorder (adhd)

Dosage: CAPSULE, EXTENDED RELEASE

More Information on Dosage

QELBREE family patents

Family Patents

34. Qulipta patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9499545 ABBVIE Piperidinone carboxamide azaindane CGRP receptor antagonists
Nov, 2031

(7 years from now)

US8754096 ABBVIE Piperidinone carboxamide azaindane CGRP receptor antagonists
Jul, 2032

(8 years from now)

US9850246 ABBVIE Process for making CGRP receptor antagonists
Mar, 2033

(8 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10117836 ABBVIE Tablet formulation for CGRP active compounds
Jan, 2035

(10 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-909) Apr 17, 2026
New Chemical Entity Exclusivity(NCE) Sep 28, 2026

Drugs and Companies using ATOGEPANT ingredient

NCE-1 date: 28 September, 2025

Market Authorisation Date: 28 September, 2021

Treatment: Preventive treatment of migraine in adults

Dosage: TABLET

More Information on Dosage

QULIPTA family patents

Family Patents

35. Rexulti patent expiration

REXULTI's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7888362 OTSUKA Piperazine-substituted benzothiophenes for treatment of mental disorders
Apr, 2026

(1 year, 8 months from now)

USRE48059 OTSUKA Piperazine-substituted benzothiophenes for treatment of mental disorders
Dec, 2028

(4 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8618109 OTSUKA Piperazine-substituted benzothiophenes for treatment of mental disorders
Apr, 2026

(1 year, 8 months from now)

US9839637 OTSUKA Piperazine-substituted benzothiophenes for treatment of mental disorders
Apr, 2026

(1 year, 8 months from now)

US8349840 OTSUKA Piperazine-substituted benzothiophenes for treatment of mental disorders
Apr, 2026

(1 year, 8 months from now)

US10307419 OTSUKA Tablet comprising 7-[4-(4-benzo[b]thiopen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof
Oct, 2032

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
M(M-186) Sep 23, 2019
New Chemical Entity Exclusivity(NCE) Jul 10, 2020
New Patient Population(NPP) Dec 27, 2024
New Indication(I-913) May 10, 2026
Pediatric Exclusivity(PED) Nov 10, 2026
M(M-14) May 08, 2027

Drugs and Companies using BREXPIPRAZOLE ingredient

NCE-1 date: 10 November, 2025

Market Authorisation Date: 10 July, 2015

Treatment: Treatment of schizophrenia in adults and pediatric patients ages 13 years and older; Treatment of schizophrenia; Adjunctive treatment of major depressive disorder (mdd)

Dosage: TABLET

How can I launch a generic of REXULTI before it's drug patent expiration?
More Information on Dosage

REXULTI family patents

Family Patents

36. Rezurock patent expiration

REZUROCK's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8357693 KADMON PHARMS LLC Pharmacokinetically improved compounds
Oct, 2029

(5 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9815820 KADMON PHARMS LLC Rho kinase inhibitors
Oct, 2033

(9 years from now)

US10183931 KADMON PHARMS LLC Rho kinase inhibitors
Oct, 2033

(9 years from now)

US10696660 KADMON PHARMS LLC Rho kinase inhibitors
Oct, 2033

(9 years from now)

US11311541 KADMON PHARMS LLC Treatment of GVHD
Apr, 2035

(10 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jul 16, 2026
Orphan Drug Exclusivity(ODE-362) Jul 16, 2028

Drugs and Companies using BELUMOSUDIL MESYLATE ingredient

NCE-1 date: 16 July, 2025

Market Authorisation Date: 16 July, 2021

Treatment: For the treatment of chronic graft versus hold disease; For the treatment of chronic graft versus host disease; Treatment of adults and pediatric patients 12 and older with sclerodermatous form of chr...

Dosage: TABLET

More Information on Dosage

REZUROCK family patents

Family Patents

37. Scemblix patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8829195 NOVARTIS Compounds and compositions for inhibiting the activity of ABL1, ABL2 and BCR-ABL1
May, 2033

(8 years from now)

US11407735 NOVARTIS Crystalline forms of N-[4-(Chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide
May, 2040

(15 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Oct 29, 2026
Orphan Drug Exclusivity(ODE-381) Oct 29, 2028
Orphan Drug Exclusivity(ODE-382) Oct 29, 2028
ODE*(ODE*) Oct 29, 2028

Drugs and Companies using ASCIMINIB HYDROCHLORIDE ingredient

NCE-1 date: 29 October, 2025

Market Authorisation Date: 29 October, 2021

Treatment: Treatment of philadelphia chromosome positive chronic myeloid leukemia (ph+cml)

Dosage: TABLET

More Information on Dosage

SCEMBLIX family patents

Family Patents

38. Syfovre patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9169307 APELLIS PHARMS Potent compstatin analogs
Nov, 2027

(3 years from now)

US7989589 APELLIS PHARMS Compstatin analogs with improved activity
Dec, 2027

(3 years from now)

US7888323 APELLIS PHARMS Potent compstatin analogs
Dec, 2027

(3 years from now)

US11661441 APELLIS PHARMS Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof
Jan, 2033

(8 years from now)

US10125171 APELLIS PHARMS Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof
Aug, 2033

(9 years from now)

US10875893 APELLIS PHARMS Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods
Nov, 2033

(9 years from now)

US11292815 APELLIS PHARMS Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods
Nov, 2033

(9 years from now)

US10035822 APELLIS PHARMS Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods
Nov, 2033

(9 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9056076 APELLIS PHARMS Method of treating age-related macular degeneration comprising administering a compstatin analog
Oct, 2026

(2 years from now)

US8168584 APELLIS PHARMS Methods of treating age-related macular degeneration by compstatin and analogs thereof
Apr, 2027

(2 years from now)

US11903994 APELLIS PHARMS Dosing regimens
Feb, 2037

(12 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Feb 22, 2026
New Chemical Entity Exclusivity(NCE) May 14, 2026

Drugs and Companies using PEGCETACOPLAN ingredient

NCE-1 date: 14 May, 2025

Market Authorisation Date: 17 February, 2023

Treatment: Treatment of geographic atrophy secondary to age-related macular degeneration by intravitreal administration of pegcetacoplan; Treatment of geographic atrophy secondary to age-related macular degenera...

Dosage: SOLUTION

More Information on Dosage

SYFOVRE family patents

Family Patents

39. Synjardy patent expiration

SYNJARDY's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7713938 BOEHRINGER INGELHEIM Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
Apr, 2027

(2 years from now)

US7579449 BOEHRINGER INGELHEIM Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
Aug, 2028

(4 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7713938

(Pediatric)

BOEHRINGER INGELHEIM Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
Oct, 2027

(3 years from now)

US7579449

(Pediatric)

BOEHRINGER INGELHEIM Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
Feb, 2029

(4 years from now)

US10610489 BOEHRINGER INGELHEIM Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
Sep, 2030

(6 years from now)

US10610489

(Pediatric)

BOEHRINGER INGELHEIM Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
Mar, 2031

(6 years from now)

US10258637 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Apr, 2034

(9 years from now)

US11813275 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Apr, 2034

(9 years from now)

US11090323 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Apr, 2034

(9 years from now)

US11833166 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Apr, 2034

(9 years from now)

US9949997 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
May, 2034

(9 years from now)

US11090323

(Pediatric)

BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Oct, 2034

(10 years from now)

US10258637

(Pediatric)

BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Oct, 2034

(10 years from now)

US9949997

(Pediatric)

BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Nov, 2034

(10 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Aug 26, 2018
M(M-174) Mar 18, 2019
New Chemical Entity Exclusivity(NCE) Aug 01, 2019
New Indication(I-739) Dec 02, 2019
New Patient Population(NPP) Jun 20, 2026
Pediatric Exclusivity(PED) Dec 20, 2026

Drugs and Companies using EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient

NCE-1 date: 20 December, 2025

Market Authorisation Date: 26 August, 2015

Treatment: Method of treating type 2 diabetes mellitus in a patient with renal impairment (45 ml/min/1.73 m2<=egfr<60 ml/min/1.73 m2) by once daily administration of 10 mg or 25 mg of empagliflozin; Method for r...

Dosage: TABLET

How can I launch a generic of SYNJARDY before it's drug patent expiration?
More Information on Dosage

SYNJARDY family patents

Family Patents

40. Synjardy Xr patent expiration

SYNJARDY XR's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7713938 BOEHRINGER INGELHEIM Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
Apr, 2027

(2 years from now)

US7579449 BOEHRINGER INGELHEIM Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
Aug, 2028

(4 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6488962 BOEHRINGER INGELHEIM Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
Jun, 2020

(4 years ago)

US7713938

(Pediatric)

BOEHRINGER INGELHEIM Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
Oct, 2027

(3 years from now)

US7579449

(Pediatric)

BOEHRINGER INGELHEIM Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
Feb, 2029

(4 years from now)

US10596120 BOEHRINGER INGELHEIM Pharmaceutical compositions
Mar, 2032

(7 years from now)

US10596120

(Pediatric)

BOEHRINGER INGELHEIM Pharmaceutical compositions
Sep, 2032

(8 years from now)

US11833166 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Apr, 2034

(9 years from now)

US10258637 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Apr, 2034

(9 years from now)

US11813275 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Apr, 2034

(9 years from now)

US11090323 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Apr, 2034

(9 years from now)

US9949997 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
May, 2034

(9 years from now)

US9949998 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Jun, 2034

(9 years from now)

US11090323

(Pediatric)

BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Oct, 2034

(10 years from now)

US10258637

(Pediatric)

BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Oct, 2034

(10 years from now)

US9949997

(Pediatric)

BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Nov, 2034

(10 years from now)

US9949998

(Pediatric)

BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Dec, 2034

(10 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Aug 01, 2019
New Indication(I-739) Dec 02, 2019
M(M-296) Jun 20, 2026
Pediatric Exclusivity(PED) Dec 20, 2026

Drugs and Companies using EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient

NCE-1 date: 20 December, 2025

Market Authorisation Date: 09 December, 2016

Treatment: Treatment of a treatment-naïve patient with inadequately controlled type 2 diabetes using a composition comprising an extended release core comprising metformin and an outer coating comprising empagli...

Dosage: TABLET, EXTENDED RELEASE

How can I launch a generic of SYNJARDY XR before it's drug patent expiration?
More Information on Dosage

SYNJARDY XR family patents

Family Patents

41. Tavneos patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8906938 CHEMOCENTRYX C5aR antagonists
Dec, 2029

(5 years from now)

US8445515 CHEMOCENTRYX C5aR antagonists
Feb, 2031

(6 years from now)

US11603356 CHEMOCENTRYX Amorphous form of a complement component C5a receptor
May, 2041

(16 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11951214 CHEMOCENTRYX Capsule formulations
Nov, 2039

(15 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Oct 07, 2026
Orphan Drug Exclusivity(ODE-377) Oct 07, 2028

Drugs and Companies using AVACOPAN ingredient

NCE-1 date: 07 October, 2025

Market Authorisation Date: 07 October, 2021

Treatment: An adjunctive treatment of adult patients with tavneos (avacopan) with severe active anca-associated vasculitis (gpa and mpa) in combination with standard therapy including glucocorticoids

Dosage: CAPSULE

More Information on Dosage

TAVNEOS family patents

Family Patents

42. Tepmetko patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8921357 EMD SERONO INC Pyridazinone derivatives
May, 2028

(3 years from now)

US8329692 EMD SERONO INC Pyrimidinyl pyridazinone derivatives
Oct, 2029

(5 years from now)

US8580781 EMD SERONO INC Pyridazinone derivatives
Mar, 2030

(5 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9284300 EMD SERONO INC Pyridazinone derivatives
Apr, 2028

(3 years from now)

US9062029 EMD SERONO INC Pyrimidinyl pyridazinone derivatives
Jul, 2028

(3 years from now)

US8658643 EMD SERONO INC Pyrimidinyl pyridazinone derivatives
Jul, 2028

(3 years from now)

US9403799 EMD SERONO INC Pyrimidinyl-pyridazinone derivatives for treating a disease which is influenced by inhibition of met kinase
Jul, 2028

(3 years from now)

US8927540 EMD SERONO INC Pyridazinone derivatives
Jul, 2028

(4 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Feb 03, 2026
Orphan Drug Exclusivity(ODE-325) Feb 03, 2028

Drugs and Companies using TEPOTINIB HYDROCHLORIDE ingredient

NCE-1 date: 03 February, 2025

Market Authorisation Date: 03 February, 2021

Treatment: Treating a solid tumor, including lung cancer, with a met alteration(s), or stabilizing or improving symptoms associated with having a solid tumor, including lung cancer, with a met alteration(s), by ...

Dosage: TABLET

More Information on Dosage

TEPMETKO family patents

Family Patents

43. Tradjenta patent expiration

TRADJENTA's oppositions filed in EPO
TRADJENTA IPR and PTAB Proceedings